↑ トップへ　← 戻る

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

90 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
2 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
3 African trypanosomiasis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
4 African trypanosomiasis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
5 African trypanosomiasis 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
10 Allograft rejection 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
11 Allograft rejection 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
12 Alzheimer disease 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
13 Alzheimer disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
14 Amoebiasis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
15 Amoebiasis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
16 Amoebiasis 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
17 Amoebiasis 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
18 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
19 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
20 Antifolate resistance 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
21 Antifolate resistance 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
22 Antigen processing and presentation 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
23 Autoimmune thyroid disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
24 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
25 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
26 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
27 C-type lectin receptor signaling pathway 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
28 Cell adhesion molecules 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
29 Cellular senescence 💬
 1件: IL1A 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
30 Chagas disease 💬
 1件: ACE 💬 D00251 💬 Captopril 8件:  6 , 17, 46, 86, 96, 97, 107, 271 💬
31 Chagas disease 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
32 Chagas disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
33 Chagas disease 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
34 Chemokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
35 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
36 Cholinergic synapse 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
37 Cholinergic synapse 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
38 Complement and coagulation cascades 💬
 1件: SERPINC1 💬 D07510 💬 Heparin 11件: 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 💬
39 Coronavirus disease - COVID-19 💬
 1件: ACE 💬 D00251 💬 Captopril 8件:  6 , 17, 46, 86, 96, 97, 107, 271 💬
40 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
41 Coronavirus disease - COVID-19 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
42 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
43 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
44 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
45 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
46 Cytokine-cytokine receptor interaction 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
47 Cytokine-cytokine receptor interaction 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
48 Cytokine-cytokine receptor interaction 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
49 Cytokine-cytokine receptor interaction 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
50 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
51 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
52 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
53 Cytosolic DNA-sensing pathway 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
54 Diabetic cardiomyopathy 💬
 1件: ACE 💬 D00251 💬 Captopril 8件:  6 , 17, 46, 86, 96, 97, 107, 271 💬
55 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
56 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
57 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
58 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
59 Epstein-Barr virus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
60 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
61 Fluid shear stress and atherosclerosis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
62 Fluid shear stress and atherosclerosis 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
63 Fluid shear stress and atherosclerosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
64 Fluid shear stress and atherosclerosis 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
65 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
66 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
67 Graft-versus-host disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
68 Graft-versus-host disease 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
69 Graft-versus-host disease 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
70 Graft-versus-host disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
71 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
72 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
73 Hematopoietic cell lineage 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
74 Hematopoietic cell lineage 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
75 Hematopoietic cell lineage 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
76 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
77 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
78 Hepatitis B 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
79 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
80 Hepatitis C 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
81 Hepatitis C 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
82 Hepatitis C 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
83 Herpes simplex virus 1 infection 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
84 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
85 Herpes simplex virus 1 infection 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
86 Herpes simplex virus 1 infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
87 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
88 HIF-1 signaling pathway 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
89 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
90 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
91 Human cytomegalovirus infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
92 Human cytomegalovirus infection 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
93 Human cytomegalovirus infection 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
94 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
95 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
96 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
97 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
98 Human papillomavirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
99 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
100 Human T-cell leukemia virus 1 infection 💬
 2件: IL1R1, IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
101 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
102 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
103 Hypertrophic cardiomyopathy 💬
 1件: ACE 💬 D00251 💬 Captopril 8件:  6 , 17, 46, 86, 96, 97, 107, 271 💬
104 IL-17 signaling pathway 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
105 IL-17 signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
106 IL-17 signaling pathway 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
107 Inflammatory bowel disease 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
108 Inflammatory bowel disease 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
109 Inflammatory bowel disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
110 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
111 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
112 Inflammatory mediator regulation of TRP channels 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
113 Influenza A 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
114 Influenza A 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
115 Influenza A 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
116 Influenza A 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
117 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
118 Intestinal immune network for IgA production 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
119 JAK-STAT signaling pathway 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
120 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
121 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
122 JAK-STAT signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
123 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
124 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
125 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
126 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
127 Legionellosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
128 Legionellosis 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
129 Leishmaniasis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
130 Leishmaniasis 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
131 Leishmaniasis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
132 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
133 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
134 Malaria 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
135 Malaria 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
136 Malaria 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
137 MAPK signaling pathway 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
138 MAPK signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
139 MAPK signaling pathway 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
140 Measles 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
141 Measles 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
142 Measles 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
143 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
144 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
145 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
146 Natural killer cell mediated cytotoxicity 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
147 Necroptosis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
148 Necroptosis 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
149 Necroptosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
150 Necroptosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
151 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
152 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
153 NF-kappa B signaling pathway 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
154 NF-kappa B signaling pathway 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
155 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
156 NOD-like receptor signaling pathway 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
157 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
158 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
159 Non-alcoholic fatty liver disease 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
160 Non-alcoholic fatty liver disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
161 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
162 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
163 Non-small cell lung cancer 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
164 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
165 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
166 Osteoclast differentiation 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
167 Osteoclast differentiation 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
168 Osteoclast differentiation 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
169 Osteoclast differentiation 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
170 Osteoclast differentiation 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
171 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
172 Pancreatic cancer 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
173 Pancreatic cancer 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
174 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
175 Pathogenic Escherichia coli infection 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
176 Pathogenic Escherichia coli infection 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
177 Pathways in cancer 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
178 Pathways in cancer 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
179 Pathways in cancer 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
180 Pathways in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
181 Pathways in cancer 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
182 Pathways of neurodegeneration - multiple diseases 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
183 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
184 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
185 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
186 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
187 Pertussis 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
188 Pertussis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
189 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
190 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
191 PI3K-Akt signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
192 PI3K-Akt signaling pathway 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
193 Primary immunodeficiency 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
194 Prion disease 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
195 Prion disease 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
196 Prolactin signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
197 Prolactin signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
198 Prostate cancer 💬
 1件: IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
199 Proteasome 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
200 Renin secretion 💬
 1件: ACE 💬 D00251 💬 Captopril 8件:  6 , 17, 46, 86, 96, 97, 107, 271 💬
201 Renin-angiotensin system 💬
 1件: ACE 💬 D00251 💬 Captopril 8件:  6 , 17, 46, 86, 96, 97, 107, 271 💬
202 Rheumatoid arthritis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
203 Rheumatoid arthritis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
204 Rheumatoid arthritis 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
205 Rheumatoid arthritis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
206 Salmonella infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
207 Salmonella infection 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
208 Shigellosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
209 Shigellosis 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
210 Shigellosis 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
211 Signaling pathways regulating pluripotency of stem cells 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
212 Signaling pathways regulating pluripotency of stem cells 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
213 Systemic lupus erythematosus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
214 Systemic lupus erythematosus 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
215 T cell receptor signaling pathway 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
216 TGF-beta signaling pathway 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
217 Th1 and Th2 cell differentiation 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
218 Th1 and Th2 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
219 Th1 and Th2 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
220 Th17 cell differentiation 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
221 Th17 cell differentiation 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
222 Th17 cell differentiation 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
223 Th17 cell differentiation 💬
 1件: IL1R1 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
224 Th17 cell differentiation 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
225 Th17 cell differentiation 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
226 Th17 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
227 Th17 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
228 TNF signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
229 TNF signaling pathway 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
230 Toll-like receptor signaling pathway 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
231 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
232 Toll-like receptor signaling pathway 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
233 Toxoplasmosis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
234 Toxoplasmosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
235 Toxoplasmosis 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
236 Transcriptional misregulation in cancer 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
237 Transcriptional misregulation in cancer 💬
 1件: IL1R2 💬 D02934 💬 Anakinra 19件:  2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
238 Tuberculosis 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
239 Tuberculosis 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
240 Tuberculosis 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
241 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
242 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
243 Type I diabetes mellitus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
244 Type I diabetes mellitus 💬
 1件: IFNG 💬 D11120 💬 Emapalumab 1件: 107 💬
245 Type I diabetes mellitus 💬
 2件: IL1A, IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬
246 Type I diabetes mellitus 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
247 Viral carcinogenesis 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
248 Viral carcinogenesis 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
249 Viral myocarditis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
250 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D10161 💬 Sarilumab 5件: 41, 46, 84, 107, 271 💬
251 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
252 Yersinia infection 💬
 1件: IL1B 💬 D09315 💬 Canakinumab 10件: 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
253 Yersinia infection 💬
 1件: IL1B 💬 D06635 💬 Rilonacept 4件: 51, 106, 107, 266 💬

先頭へ